The HLB-led group owns nearly half of vaccine product developer Immunomic Therapeutics following a $61.3m commitment this year.
US-based vaccine developer Immunomic Therapeutics completed a $61.3m financing round yesterday that was led by pharmaceutical firm HLB.
The HLB-led consortium had supplied an initial $10m for the round in February this year and now owns 47.6% of Immunomic. The deal gives the corporate the option to provide additional capital in the coming months.
Immunomic has created vaccine development technology dubbed Universal Intracellular Targeted Expression (Unite) that exploits the body’s biochemistry to generate responses from the immune system.
The technology…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
